Coppell Advisory Solutions LLC Buys 27,037 Shares of Omnicell, Inc. $OMCL

Key Points

• Coppell Advisory Solutions LLC increased its stake in Omnicell, Inc. by 5,343.3% during Q1, owning approximately 0.06% of the company, valued at $1.05 million.
• Omnicell's EPS for the last quarter was reported at $0.45, exceeding analysts' estimates of $0.30, with revenue of $290.56 million, showing a 5.0% increase compared to the same quarter last year.
• Analysts currently have a consensus rating of "Moderate Buy" for Omnicell, with a price target averaging $46.71, after several analyst revisions on price targets and ratings.

Coppell Advisory Solutions LLC boosted its holdings in shares of Omnicell, Inc. (NASDAQ:OMCL - Free Report) by 5,343.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 27,543 shares of the company's stock after buying an additional 27,037 shares during the quarter. Coppell Advisory Solutions LLC owned approximately 0.06% of Omnicell worth $1,053,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Point72 Hong Kong Ltd bought a new position in shares of Omnicell in the fourth quarter worth approximately $101,000. AlphaQuest LLC boosted its position in shares of Omnicell by 79.0% in the first quarter. AlphaQuest LLC now owns 6,400 shares of the company's stock worth $224,000 after purchasing an additional 2,824 shares during the period. New Age Alpha Advisors LLC bought a new position in shares of Omnicell in the first quarter worth approximately $233,000. EntryPoint Capital LLC boosted its position in shares of Omnicell by 21.6% in the first quarter. EntryPoint Capital LLC now owns 6,671 shares of the company's stock worth $233,000 after purchasing an additional 1,184 shares during the period. Finally, EP Wealth Advisors LLC bought a new position in shares of Omnicell in the first quarter worth approximately $245,000. 97.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

OMCL has been the subject of a number of recent analyst reports. Bank of America upped their price target on shares of Omnicell from $30.00 to $34.00 and gave the stock a "neutral" rating in a research report on Friday, May 23rd. Wells Fargo & Company upped their price target on shares of Omnicell from $37.00 to $40.00 and gave the stock an "overweight" rating in a research report on Monday, July 21st. Wall Street Zen lowered shares of Omnicell from a "strong-buy" rating to a "buy" rating in a research report on Saturday, August 9th. Finally, Piper Sandler dropped their target price on shares of Omnicell from $57.00 to $55.00 and set an "overweight" rating for the company in a research report on Monday, August 11th. Four investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $46.71.

Omnicell Price Performance

Omnicell stock traded down $1.45 during mid-day trading on Friday, reaching $31.83. 492,448 shares of the company's stock traded hands, compared to its average volume of 490,780. The company has a market cap of $1.46 billion, a price-to-earnings ratio of 63.66, a PEG ratio of 6.95 and a beta of 0.82. The stock has a 50 day moving average of $30.71 and a two-hundred day moving average of $31.00. The company has a quick ratio of 1.24, a current ratio of 1.42 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $22.66 and a 12-month high of $55.74.

Omnicell (NASDAQ:OMCL - Get Free Report) last released its quarterly earnings results on Thursday, July 31st. The company reported $0.45 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.30 by $0.15. The company had revenue of $290.56 million for the quarter, compared to the consensus estimate of $275.57 million. Omnicell had a net margin of 2.01% and a return on equity of 4.27%. Omnicell's revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.51 earnings per share. Omnicell has set its FY 2025 guidance at 1.400-1.650 EPS. Q3 2025 guidance at 0.300-0.370 EPS. Equities analysts forecast that Omnicell, Inc. will post 1.09 earnings per share for the current year.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.